Medicxi Ventures Management 13F-HR Quarterly holdings report by institutional manager

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL

OMB Number:		3235-0006
Expires:	Oct 31, 2018
Estimated average burden
hours per response:		23.8

COLUMN 1	COLUMN 2	COLUMN 3	COLUMN 4	COLUMN 5			COLUMN 6	COLUMN 7	COLUMN 8
			VALUE	SHRS OR	SH/	PUT/	INVESTMENT	OTHER	VOTING AUTHORITY
NAME OF ISSUER	TITLE OF CLASS	CUSIP	(x$1000)	PRN AMT	PRN	CALL	DISCRETION	MANAGER	SOLE	SHARED	NONE
OBSEVA SA	COM	H5861P103	5,102	1,570,000	SH		SOLE	1,2,3	1,570,000	0	0
VAXCYTE INC	COM	92243G108	37,277	1,887,478	SH		SOLE	1,2,3	1,887,478	0	0
MERUS N V	COM	N5749R100	33,424	1,600,000	SH		SOLE	1,2,3	1,600,000	0	0
PHATHOM PHARMACEUTICALS INC	COM	71722W107	77,669	2,067,861	SH		SOLE	1,2,3	2,067,861	0	0
CHECKMATE PHARMACEUTICALS IN	COM	162818108	18,231	1,501,716	SH		SOLE	1,2,3	1,501,716	0	0